In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

From the Holderness Family to Grandma C, social media personalities around Raleigh and Durham explain what will get lost if TikTok goes away Sunday.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...

Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...